ProMetic Life Sciences   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Laval Canada (1992)

Organization Overview

First Clinical Trial
2014
NCT02312180
First Marketed Drug
2021
plasminogen (Ryplazim)
First NDA Approval
2021
plasminogen (Ryplazim)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ProMetic BioSciences Inc. | Prometic Biotherapeutics, Inc. | ProMetic BioTherapeutics, Inc | ProMetic BioTherapeutics, Inc. | ProMetic Life Sciences Inc. | ProMetic Pharma SMT Limited | Prometic Pharma SMT Ltd.

Active Ingredients

Marketed Drugs (1)

plasminogen (Ryplazim) (2021 NDA)

Drugs in Phase 3 Trials (6)

Key: ProMetic Life Sciences (3) Acquired (3)

bacille calmette-guerin (1 trial)

immune globulin (human) (Gamastan) (1 trial)

mitomycin (mutamycin) (1 trial)

mycobacterial cell wall-dna complex (3 trials)

pbi-4050 (7 trials)

plasminogen (Ryplazim) (4 trials)

Drugs in Phase 1 Trials (3)

Key: ProMetic Life Sciences (2) Acquired (1)

azacitidine (vidaza) (1 trial)

midazolam (versed) (1 trial)

pbi-4547 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alstrom Syndrome (Phase 3)

Coagulation Protein Disorders (Phase 3)

Cystic Fibrosis (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Immunologic Deficiency Syndromes (Phase 3)

Inflammation (Phase 2)

Metabolic Syndrome (Phase 2)

Pulmonary Fibrosis (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 9